If you made any changes in Pure these will be visible here soon.

Personal profile

Scholarly biography

Dr Alison Lansley is a Principal Lecturer in Biopharmaceutics in the School of Pharmacy and Biomolecular Sciences at the University of Brighton. She graduated with a degree in Pharmacy and then studied the effect of preservatives on nasal mucociliary clearance for her PhD (both at the University of Brighton). After this, she went on to research ciliary activity and the role of calcium ions in intercellular communication at the University of California, Los Angeles.

Subsequently, Alison took up a postdoctoral and then lecturing position at King’s College London where she studied drug delivery to the airways. After a career break she was awarded a Daphne Jackson fellowship at the University of Sussex and from this she moved to her current position where her research interests include the effect of mucus on drug absorption in the respiratory tract and factors affecting mucociliary clearance, as well as optimising the treatment of asthma in children.

She teaches biopharmaceutics to undergraduate and postgraduate students and serves on the committee of the Inhalation Focus Group of the Academy of Pharmaceutical Sciences. She has supervised PhD students and postdoctoral researchers with funding from research councils, charities and industry and has published papers and book chapters on pulmonary and nasal drug delivery.

Approach to teaching

I teach on a wide variety of courses, both undergraduate and postgraduate, including the four-year pharmacy degree (MPharm). I specialise in biopharmaceutics and mainly teach about the factors affecting the bioavailability of drugs delivered by a number of different routes and how this can be modelled in vitro. The features of these routes and the physiocochemical properties of the drugs are considered as well as the formulating for modified release. I aim to engage the students by making my lectures interactive, with lots of questions and answers. I support this with Powerpoint slides and podcasts which student feedback indicates are particularly popular. I recently won a student-nominated, University of Brighton award for Excellence in Facilitating and Empowering Learning.

Research interests

I am interested in the delivery of drugs and particles to the nose and lungs, particularly the use of in vivo-reflective in vitro cell culture models of the airway epithelium; the barrier to drug absorption. My interest in this area of pulmonary biopharmaceutics began in 1991; having worked on the Caco-2 cell culture model of the intestine I was interested in developing a similar model of the nose and/or lung. I have used the 16HBE14o- cell line to study drug absorption, including the absorption of drugs from nanoparticles, and drug toxicity. More recently, our group has been studying the effect of mucus on airway drug absorption using two mucus-secreting cell lines (SPOC1 and UNCN3T) and also the effect of drugs and other chemicals on mucus secretion as a measure of irritancy. In addition, I am interested in the role of mucociliary clearance on airway drug delivery, particularly the effect of formulation variables, air pollution and other chemicals on this primary defence mechanism of the nose and lung. I am also interested in the bioavailability of inhaled drugs in children and adults and how this can be optimised.

Supervisory Interests

I am interested the in the absorption of drugs and particulates (including air pollution) in the airway and brain and their effect on permeability (cell junctions).  A particular interest is the role of mucus and mucociliary clearance in drug/particulate delivery to the airway. I have supervised 11 successful PhD students and 5 postdoctoral scientists. Current projects available for supervision include: 

1. The delivery of drugs and particles to the nose and lungs, particularly the use of in vivo-reflective in vitro cell culture models of the airway epithelium and the role mucus and mucociliary clearance plays in drug and particulate delivery to the airways.

2. The bioavailability of inhaled drugs in children and adults and how this can be optimised in asthma and COPD.

3. Determining the impact of ultra-fine particulate air pollution (UFPs) on mucus secretion, ciliary activity and epithelial permeability in the young and ageing lung. Do UFPs accelerate lung ageing?

4. The mechanisms by which air pollution (ultrafine particles) crosses the blood brain barrier.

Keywords

  • RS Pharmacy and materia medica
  • drug delivery to nose and lung, mucociliary clearance, toxicology

Fingerprint Dive into the research topics where Alison Lansley is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Open Access
File
  • Nasal drug delivery

    Lansley, A. & Martin, G., 1 Jan 2018, Aulton’s Pharmaceutics: The Design and Manufacture of Medicines (International edition). Aulton, M. & Taylor, K. (eds.). Edinburgh: Elsevier Ltd, p. 671-689 19 p.

    Research output: Chapter in Book/Conference proceeding with ISSN or ISBNChapter

    Open Access
    File
  • How can we optimise inhaled beta2 agonist dose as 'reliever' medicine for wheezy pre-school children? Study protocol for a randomised controlled trial

    Mukhopadhyay, S., Seddon, P., Earl, G., Wileman, E., Symes, L., Olden, C., Alberti, C., Bremner, S., Lansley, A., Palmer, C. N. A. & Beydon, N., 11 Nov 2016, In : Trials. 17

    Research output: Contribution to journalArticle

    Open Access
    File
  • Nasal drug delivery

    Martin, G. & Lansley, A., 1 Jan 2013, Aulton’s Pharmaceutics: The Design and Manufacture of Medicines (International edition). Edinburgh: Churchill Livingstone, p. 657-674 18 p.

    Research output: Chapter in Book/Conference proceeding with ISSN or ISBNChapter